Astellas Pharma Inc. announced consolidated earnings results for three quarters ended December 31, 2016. For the nine months, the company reported sales of JPY 1,005,587 million against JPY 10,656,666 million a year ago. Core operating profit was JPY 2,418,370 million against JPY 2,338,630 million a year ago. Core profit for the period was JPY 1,771,890 million against JPY 1,693,790 million a year ago. Basic core earnings per share were JPY 83.62 against JPY 78.16 a year ago. Sales in the first nine months of fiscal year 2016 decreased by 5.6% compared to those in the corresponding period of the previous fiscal year. Sales decreased due to the impact of foreign exchange as well as the impact of the NHI drug price revision in Japan enforced in April 2016. On a constant currency basis, however, sales increased by approximately 3% year-on-year.